Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels

Summary Background and Aims Current guidelines recommend long‐term nucleot(s)ide analogue (NA) therapy for patients with HBeAg‐negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss. Methods We performed a prospective multi‐...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2022-07, Vol.56 (2), p.310-320
Hauptverfasser:	Hall, Samuel A. L., Burns, Gareth S., Anagnostou, Despina, Vogrin, Sara, Sundararajan, Vijaya, Ratnam, Dilip, Levy, Miriam T., Lubel, John S., Nicoll, Amanda J., Strasser, Simone I., Sievert, William, Desmond, Paul V., Ngu, Meng C., Angus, Peter, Sinclair, Marie, Meredith, Christopher, Matthews, Gail, Revill, Peter A., Jackson, Kathy, Littlejohn, Margaret, Bowden, D. Scott, Locarnini, Stephen A., Visvanathan, Kumar, Thompson, Alexander J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Cohort Studies DNA, Viral Female Hepatitis B e Antigens Hepatitis B Surface Antigens Hepatitis B virus - genetics Hepatitis B, Chronic - diagnosis Hepatitis B, Chronic - drug therapy Humans Male Middle Aged Prospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background and Aims Current guidelines recommend long‐term nucleot(s)ide analogue (NA) therapy for patients with HBeAg‐negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss. Methods We performed a prospective multi‐centre cohort study of stopping NA therapy. Inclusion criteria were HBeAg‐negative CHB, the absence of cirrhosis and HBVDNA
ISSN:	0269-2813 1365-2036
DOI:	10.1111/apt.16968